СИМПАТИЧЕСКАЯ НЕРВНАЯ СИСТЕМА И АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ: НОВЫЕ ДАННЫЕ, ДАЛЬНЕЙШИЕ ПЕРСПЕКТИВЫ
https://doi.org/10.18705/1607-419X-2014-20-2-66-74
Аннотация
Опубликовано с разрешения редакции журнала «Кардиология в Польше», 2013; 71, 5: 441–446; DOI: 10.5603/RH.2013.0089
Copyright © Polskie Towarzystwo Kardiologiczne
Перевод: Л.С. Коростовцева, Н.Э. Звартау
Об авторах
Д. Херинг
Медицинский университет, Гданьск
Польша
Польша
Контактная информация: (Dagmara Hering, MD, PhD, Department of Hypertension and Diabetology, Hypertension Unit, Medical University of Gdansk), Medical University of Gdansk ul. Dębinki 7c, 80–952 Gdańsk, Poland. Tel.: + 48 58 349–2527.Fax: + 48 58 349–2601, e-mail: hering@gumed.edu.pl.
К. Наркевич
Медицинский университет, Гданьск
Польша
Польша
Список литературы
1. Hering D., Esler M.D., Krum H. et al. Recent advances in the treatment of hypertension // Expert Rev. Cardiovasc. Ther. — 2011. — Vol. 9. — P. 729–744.
2. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data // Lancet. — 2005. —Vol. 365. — P. 217–223.
3. Bertoia M.L., Waring M.E., Gupta P.S. et al. Implications of new hypertension guidelines in the United States // Hypertension. — 2012. — Vol. 60. — P. 639–644.
4. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J. et al. Executive summary: heart disease and stroke statistics: 2013 update: a report from the American Heart Association // Circulation. —2013. — Vol. 127. — P. 143–152.
5. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Hypertension. — 2008. — Vol. 51. — P. 1403–1419.
6. Pierdomenico S.D., Lapenna D., Bucci A. et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension // Am. J. Hypertens. — 2005. — Vol. 18. — P. 1422–1428.
7. Witkowski A., Januszewicz A., Imiela J. et al. Catheter-based renal sympathetic denervation for the treatment of resistant arterial hypertension in Poland: experts consensus statement. Kardiol. Pol. — 2011. — Vol. 69. — P. 1208–1211.
8. Daugherty S.L., Powers J.D., Magid D.J. et al. Incidence and prognosis of resistant hypertension in hypertensive patients // Circulation. — 2012. — Vol. 125. — P. 1635–1642.
9. Daugherty S.L., Powers J.D., Magid D.J. et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension // Hypertension. — 2012. — Vol. 60. — P. 303–309.
10. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies // Lancet. — 2002. — Vol. 360. — P. 1903–1913.
11. Esler M., Jennings G., Biviano B. et al. Mechanism of elevated plasma noradrenaline in the course of essential hypertension // J. Cardiovasc. Pharmacol. — 1986. — Vol. 8, suppl. 5. — P. S39–S43.
12. Julius S., Nesbitt S. Sympathetic overactivity in hypertension. A moving target // Am. J. Hypertens. — 1996. —Vol. 9. — P. 113S–120S.
13. Greenwood J.P., Stoker J.B., Mary D.A. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease // Circulation. — 1999. — Vol. 100. — P. 1305–1310.
14. Mancia G., Grassi G., Giannattasio C., Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage // Hypertension. — 1999. — Vol. 34. — P. 724–728.
15. Anderson E.A., Sinkey C.A., Lawton W.J., Mark A.L. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings // Hypertension. —
16. — Vol. 14. — P. 177–183.
17. Esler M., Lambert G., Jennings G. Regional norepinephrine turnover in human hypertension // Clin. Exp. Hypertens. A. — 1989. — Vol. 11, suppl. 1. — P. 75–89.
18. Schlaich M.P., Lambert E., Kaye D.M. et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation // Hypertension. — 2004. — Vol. 43. — P. 169–175.
19. Hering D., Kara T., Kucharska W. et al. High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests // Blood Press. — 2013. — Jan 23 [Epub ahead of print].
20. Schlaich M.P., Kaye D.M., Lambert E. et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy // Circulation. — 2003. — Vol. 108. —P. 560–565.
21. Grassi G., Seravalle G., Quarti-Trevano F. et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction // Hypertension. — 2009. — Vol. 53. —P. 205–209.
22. Zoccali C., Mallamaci F., Parlongo S. et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease // Circulation. — 2002. —Vol. 105. — P. 1354–1359.
23. Schlaich M.P., Sobotka P.A., Krum H. et al. Renal sympathetic-nerve ablation for uncontrolled hypertension // N. Engl.J. Med. — 2009. — Vol. 361. — P. 932–934.
24. Hering D., Lambert E.A., Marusic P. et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension // Hypertension. — 2013. —Vol. 61. — P. 457–464.
25. Narkiewicz K. Układ współczulny a nadciśnienie tętnicze.Via Medica, Gdańsk 2001.
26. Parmer R.J., Cervenka J.H., Stone R.A. Baroreflex sensitivity and heredity in essential hypertension // Circulation. —1992. — Vol. 85. — P. 497–503.
27. Rea R.F., Hamdan M. Baroreflex control of muscle sympathetic nerve activity in borderline hypertension // Circulation. — 1990. — Vol. 82. — P. 856–862.
28. Trzebski A., Tafil M., Zoltowski M., Przybylski J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension // Cardiovasc. Res. — 1982. — Vol. 16. —P. 163–172.
29. Somers V.K., Mark A.L., Abboud F.M. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects // Hypertension. — 1988. — Vol. 11. — P. 608–612.
30. Sinski M., Lewandowski J., Przybylski J. et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension // Hypertens. Res. —2012. — Vol. 35. — P. 487–491.
31. Ferrier C., Esler M.D., Eisenhofer G. et al. Increased norepinephrine spillover into the jugular veins in essential hypertension // Hypertension. — 1992. — Vol. 19. — P. 62–69.
32. DiBona G.F. The sympathetic nervous system and hypertension: recent developments // Hypertension. — 2004. — Vol. 43. — P. 147–150.
33. Schmieder R.E., Redon J., Grassi G. et al. ESH position paper: renal denervation — an interventional therapy of resistant hypertension // J. Hypertens. — 2012. — Vol. 30. — P. 837–841.
34. Parati G.I.J.J., Gavish B. Respiration and blood pressure.Chapter A43. In: Izzo JL, Sica D, Black HR eds. Hypertension primer. 4th ed. Lippincott, Williams, and Wilkins, Baltimore 2008. — P. 136–138.
35. Oneda B., Ortega K.C., Gusmao J.L., Araujo T.G.,Mion D., Jr. Sympathetic nerve activity is decreased during deviceguided slow breathing // Hypertens. Res. — 2010. — Vol. 33. —P. 708–712. 35. Hering D.,
36. Kucharska W., Kara T. et al. Effects of acute and long-term slow breathing exercise on muscle sympatheticnerve activity in untreated male patients with hypertension // J. Hypertens. — 2013. — Vol. 31. — P. 739–746.
37. Krum H., Schlaich M., Whitbourn R. et al. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study // Lancet. — 2009. — Vol. 373. — P. 1275–1281.
38. Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial // Lancet. —2010. — Vol. 376. — P. 1903–1909.
39. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months // Hypertension. —2011. — Vol. 57. — P. 911–917.
40. Brandt M.C., Mahfoud F., Reda S. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension // J. Am.Coll. Cardiol. — 2012. — Vol. 59. — P. 901–909.
41. Mortensen K., Franzen K., Himmel F. et al. Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study // J. Clin. Hypertens. (Greenwich). —2012. — Vol. 14. — P. 861–870.
42. Hering D., Walton A., Krum H. et al. Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies // Int. J. Cardiol. —2012. — Vol. 159. — P. e35–e36.
43. Witkowski A., Prejbisz A., Florczak E. et al. Effects of renal sympathetic denervation on blood ressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea // Hypertension. — 2011. — Vol. 58. — P. 559–565.
44. Hering D., Esler M.D., Schlaich M.P. Effects of renal denervation on insulin resistance // Expert Rev. Cardiovasc. Ther. —2012. — Vol. 10. — P. 1381–1386.
45. Hering D., Mahfoud F., Walton A.S. et al. Renal denervation in moderate to severe CKD // J. Am. Soc. Nephrol. — 2012. — Vol. 23. — P. 1250–1257.
46. Lambert G.W., Hering D., Esler M.D. et al. Health-related quality of life after renal denervation in patients with treatmentresistant hypertension // Hypertension. — 2012. — Vol. 60. —P. 1479–1484.
47. Scheffers I.J., Kroon A.A., Schmidli J. et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study // J. Am. Coll. Cardiol. —2010. — Vol. 56. — P. 1254–1258.
48. Bakris G.L., Nadim M.K., Haller H. et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial // J. Am. Soc. Hypertens. — 2012. — Vol. 6. — P. 152–158.
49. Heusser K., Tank J., Engeli S. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients // Hypertension. — 2010. — Vol. 55. — P. 619–626.
50. Pereira E.A., Wang S., Paterson D.J. et al. Sustained reduction of hypertension by deep brain stimulation // J. Clin. Neurosci. — 2010. — Vol. 17. — P. 124–127.
51. Patel N.K., Javed S., Khan S. et al. Deep brain stimulation relieves refractory hypertension // Neurology. — 2011. — Vol. 76. — P. 405–407.
Рецензия
Для цитирования:
Херинг Д., Наркевич К. СИМПАТИЧЕСКАЯ НЕРВНАЯ СИСТЕМА И АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ: НОВЫЕ ДАННЫЕ, ДАЛЬНЕЙШИЕ ПЕРСПЕКТИВЫ. Артериальная гипертензия. 2014;20(2):66-74. https://doi.org/10.18705/1607-419X-2014-20-2-66-74
For citation:
Hering D., Narkiewicz K. SYMPATHETIC NERVOUS SYSTEM AND ARTERIAL HYPERTENSION: NEW PERSPECTIVES, NEW DATA. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(2):66-74. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-2-66-74
Просмотров:
1131
Послать статью по эл. почте 